Sugi Predict

Sugi Predict / Compounds / SCHEMBL601515

SCHEMBL601515

SCHEMBL601515

Cc1ccc2[nH]c(C(=O)N3CCN(C)CC3)cc2c1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 8)

geneUniProtsupporting neighboursconfidence
▸ HRH4 Q9H3N8 14/20 1.00
▸ NPC1 O15118 1/20 0.78
▸ RAB9A P51151 1/20 0.78
▸ AKR1C3 P42330 4/20 0.75
▸ HRH3 Q9Y5N1 3/20 0.74
▸ HRH1 P35367 1/20 0.74
▸ MEN1 O00255 1/20 0.73
▸ KMT2A Q03164 1/20 0.73

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6142003 0.90 HRH4 (0.81) HRH4NPC1RAB9AAKR1C3HRH3
SCHEMBL14845693 0.89 NPC1 (0.97) HRH4NPC1RAB9AAKR1C3HRH3
SCHEMBL12334169 0.87 NPC1 (1.00) HRH4NPC1RAB9AAKR1C3HRH3
SCHEMBL6130834 0.86 HRH4 (1.00) HRH4HRH3HRH1
SCHEMBL17938665 0.86 NPC1 (0.78) HRH4NPC1RAB9AAKR1C3HRH3
SCHEMBL13174204 0.86 AKR1C3 (1.00) HRH4NPC1RAB9AAKR1C3HRH3
SCHEMBL612331 0.85 AKR1C3 (0.78) HRH4NPC1RAB9AAKR1C3HRH3
SCHEMBL604107 0.85 HRH4 (1.00) HRH4HRH3HRH1MEN1KMT2A
Jnj-7777120 SCHEMBL186434 0.85 HRH4 (1.00) HRH4HRH3HRH1KMT2A
SCHEMBL6141960 0.85 HRH4 (1.00) HRH4HRH3HRH1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 53 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1373204-B1 HETEROCYCLIC COMPOUNDS JANSSEN PHARMACEUTICALS INC (US) 2016-10-26 — — EP claimed
CN-1694703-A Use of indolyl derivatives for the manufacture of a medicament for the treatment allergic rhinitis JANSSEN PHARMACEUTICA NV (BE) 2005-11-09 — — CN claimed
EP-1551406-A1 USE OF INDOLYL DERIVATIVES FOR THE MANUFACTURE OF A MEDICAMENT FOR THE TREATMENT OF ALLERGIC RHINITIS JANSSEN PHARMACEUTICA N.V. (BE) 2005-07-13 — — EP claimed
US-6803362-B2 ANTIHISTAMINES SUCH AS (5-CHLORO-1H-INDOL-2-YL)-(4-METHYL-PIPERAZIN-1-YL)-METHANONE, USED AS ANTIINFLAMMATORY, ANTIARTHRITIC OR BRONCHODILATOR AGENTS AND/OR IMMUNOLOGY MODULATORS ORTHO-MCNEIL PHARMACEUTICAL INC. 2004-10-12 — — US claimed
US-20040132715-A1 Method to treat allergic rhinitis DUNFORD PAUL J (US) 2004-07-08 — — US claimed
WO-2004022061-A1 USE OF INDOLYL DERIVATIVES FOR THE MANUFACTURE OF A MEDICAMENT FOR THE TREATMENT ALLERGIC RHINITIS JANSSEN PHARMACEUTICA, N.V. (BE) 2004-03-18 — — WO claimed
EP-1373204-A2 HETEROCYCLIC COMPOUNDS Ortho-McNeil Pharmaceutical, Inc. (US) 2004-01-02 — — EP claimed
US-20030207893-A1 Heterocyclic compounds ORTHO MCNEIL PHARMACEUTICAL, INC. 2003-11-06 — — US claimed
WO-2002072548-A2 HETEROCYCLIC COMPOUNDS AND THEIR USE AS HISTAMINE H4 LIGANDS. ORTHO-MCNEIL PHARMACEUTICAL, INC. (US) 2002-09-19 — — WO claimed
US-20230127655-A1 MODULATORS OF ATP-BINDING CASSETTE TRANSPORTERS VERTEX PHARMACEUTICALS INCORPORATED (US) 2023-04-27 — — US disclosed
US-10195195-B2 Selective histamine H4 receptor antagonists for the treatment of vestibular disorders INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE) (FR) 2019-02-05 — — US disclosed
EP-3378476-A1 H4 RECEPTOR INHIBITORS FOR TREATING TINNITUS Sensorion (FR) 2018-09-26 — — EP disclosed
US-20170189389-A1 MODULATORS OF ATP-BINDING CASSETTE TRANSPORTERS VERTEX PHARMACEUTICALS INCORPORATED (US) 2017-07-06 — — US disclosed
US-9688989-B2 H4 receptor inhibitors for treating tinnitus SENSORION (FR) 2017-06-27 — — US disclosed
US-20040132715-A1 Method to treat allergic rhinitis DUNFORD PAUL J (US) 2004-07-08 — — US disclosed
WO-2004022061-A1 USE OF INDOLYL DERIVATIVES FOR THE MANUFACTURE OF A MEDICAMENT FOR THE TREATMENT ALLERGIC RHINITIS JANSSEN PHARMACEUTICA, N.V. (BE) 2004-03-18 — — WO disclosed
WO-2004021999-A2 USE OF HISTAMINE H4 RECEPTOR MODULATORS FOR THE TREATMENT OF ALLERGY AND ASTHMA JANSSEN PHARMACEUTICA, N.V. (BE) 2004-03-18 — — WO disclosed
EP-1373204-A2 HETEROCYCLIC COMPOUNDS Ortho-McNeil Pharmaceutical, Inc. (US) 2004-01-02 — — EP disclosed
US-20030207893-A1 Heterocyclic compounds ORTHO MCNEIL PHARMACEUTICAL, INC. 2003-11-06 — — US disclosed
WO-2002072548-A2 HETEROCYCLIC COMPOUNDS AND THEIR USE AS HISTAMINE H4 LIGANDS. ORTHO-MCNEIL PHARMACEUTICAL, INC. (US) 2002-09-19 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170189389-A1 MODULATORS OF ATP-BINDING CASSETTE TRANSPORTERS CFTR, ABCB1, ABCC2 HRH4 2082/4885NPC1 38/4885RAB9A 2071/4885
US-20040132715-A1 Method to treat allergic rhinitis HRH2, HRH4, HRH1 HRH4 2/4885NPC1 477/4885RAB9A 2245/4885
US-20230127655-A1 MODULATORS OF ATP-BINDING CASSETTE TRANSPORTERS CFTR, ABCB1, ABCC2 HRH4 2082/4885NPC1 38/4885RAB9A 2071/4885
US-20030207893-A1 Heterocyclic compounds AADAC, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, NQO1 HRH4 1508/4885NPC1 383/4885RAB9A 1924/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.